Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

GBI Research, the leading business intelligence provider, has released its latest research, “Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar”, which provides insights into bone metabolic disease therapeutics until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Paget’s disease of bone, hyperparathyroidism and bone metastases. The report also provides the share of generics in global bone metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each of the four indications. The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. The report also includes insights into the bone metabolic diseases R&D product pipeline and explores the competitive landscape, including major players in the bone metabolism therapeutics market. Finally, the report also includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market.

GBI Research’s analysis shows that the overall global bone metabolism therapeutics market for the four indications (which includes osteoporosis, Paget’s disease of bone, hyperparathyroidism and bone metastases) was valued at $15 billion in 2010, growing from $10.1 billion in 2002 and indicating a CAGR of 5.2%. GBI Research forecasts the market to grow at a CAGR of 7.7% between 2010 and 2018 to record a sales value of $27.1 billion by 2018. The growth in the bone metabolism therapeutics market is mainly due to the contribution of osteoporosis market. The revenue of osteoporosis market alone has approximately 68% of the total bone metabolism revenue. So, the global bone metabolism market is growing inspite of the declining market nature of the rest of therapeutics areas discussed here.

Report Highlights
Osteoporosis Market Boosts Global Bone Metabolism Industry.

The osteoporosis therapeutics market is the primary reason for the continued growth of the global bone metabolism sector, according to a report from specialists in healthcare analysis, GBI Research.

The new report* shows that the osteoporosis treatment sector accounted for 68% of worldwide bone metabolism revenue for 2010 – far out outweighing the other components of the market, Paget's disease of bone, hyperparathyroidism and bone metastases.

The strong performance of the osteoporosis market is expected to continue, with GBI Research predicting it will help the overall bone metabolism therapeutics market reach a value of $27.1 billion by 2018.

Due to a strong pipeline, however, the bone metastases market is expected to contribute more significantly in the coming years. GBI Research’s report indicates that while the bone metastases treatments available at the moment are adequate, there are gaps in for these potentially impressive options.

There are currently 47 molecules in various stages of clinical development for bone metastases and many of these are First-In-Class.

Xeva is expected to make a big impact in the European market following market authorisation, whereas late stage pipeline molecule, Xgeva, has been approved and is currently making an impression in the US and Japan. Molecules Alpharadin and Orazol, both expected to hit in 2014, also look very promising.

In contrast, the global hyperparathyroidism therapeutics is expected to show less impressive growth, declining at a negative CAGR of 1.3% from $1.32 billion in 2010 to $1.17 billion in 2018. This downturn is attributed primarily to the patent expiry of the three approved treatments, Sensipar, Zemplar and Hectorol during this time period.

* Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

This report provides insights into bone metabolic disease therapeutics until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. It provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Paget’s disease of bone, hyperparathyroidism and bone metastases. The report also provides the share of generics in global bone metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each of the four indications.

The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. It also includes insights into the bone metabolic diseases R&D product pipeline and explores the competitive landscape, including major players in the bone metabolism therapeutics market. Finally, the report includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market.